Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05744466 · ClinicalTrials.gov registry record
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
A clinical trial of Psoriasis, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT05744466: Recruiting study of Psoriasis, sponsored by Bristol-Myers Squibb.
NCT05744466 is a study of Psoriasis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,500 participants, above the 477-participant average among 125 other Psoriasis trials with a reported enrollment target (214% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05744466, a study of Psoriasis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Conditions Studied
Interventions
- DRUG Deucravacitinib
- DRUG Apremilast
Study Locations (1)
Massachusetts
- Local Institution - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2027-12-10 |
What NCT05744466 shows while recruiting
NCT05744466 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 477-participant average among 125 other Psoriasis trials with a reported enrollment target (214% higher).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Deucravacitinib is the first listed.
NCT05744466 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05744466 about?
NCT05744466 is a clinical study titled "A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis". The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
What is the current status of trial NCT05744466?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-09-30. Estimated completion is 2027-12-10.
What conditions does trial NCT05744466 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05744466?
The interventions under investigation include: Deucravacitinib (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT05744466?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05744466 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05744466's enrollment target sits among peer trials
1,500 6th of 125 higher than 120 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI